These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 7852256)

  • 1. Methadone withdrawal psychosis.
    Levinson I; Galynker II; Rosenthal RN
    J Clin Psychiatry; 1995 Feb; 56(2):73-6. PubMed ID: 7852256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of symptom complaints in methadone maintenance patients.
    Dyer KR; White JM
    Addiction; 1997 Nov; 92(11):1445-55. PubMed ID: 9519488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychosis after ultrarapid opiate detoxification.
    Shreeram SS; McDonald T; Dennison S
    Am J Psychiatry; 2001 Jun; 158(6):970. PubMed ID: 11384923
    [No Abstract]   [Full Text] [Related]  

  • 4. Influence of the dose on the severity of opiate withdrawal symptoms during methadone detoxification.
    Glasper A; Gossop M; de Wet C; Reed L; Bearn J
    Pharmacology; 2008; 81(2):92-6. PubMed ID: 17952010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unexpected delirium during Rapid Opioid Detoxification (ROD).
    Golden SA; Sakhrani DL
    J Addict Dis; 2004; 23(1):65-75. PubMed ID: 15077841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans.
    Donny EC; Walsh SL; Bigelow GE; Eissenberg T; Stitzer ML
    Psychopharmacology (Berl); 2002 May; 161(2):202-12. PubMed ID: 11981600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acetyl-L-carnitine in the management of pain during methadone withdrawal syndrome.
    Janiri L; Martinotti G; Tonioni F; Ghelardini C; Nicolai R; Galeotti N; Mosconi L; Calvani M; Bartolini A; Iannoni E
    Clin Neuropharmacol; 2009; 32(1):35-40. PubMed ID: 18978503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse.
    Moncrieff J
    Acta Psychiatr Scand; 2006 Jul; 114(1):3-13. PubMed ID: 16774655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasability and safety of transfer from racemic methadone to (R)-methadone in primary care: clinical results from an open study.
    Soyka M; Zingg C
    World J Biol Psychiatry; 2009; 10(3):217-24. PubMed ID: 19629858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of buprenorphine and methadone in the treatment of opiate withdrawal: possible advantages of buprenorphine for the treatment of opiate-benzodiazepine codependent patients?
    Reed LJ; Glasper A; de Wet CJ; Bearn J; Gossop M
    J Clin Psychopharmacol; 2007 Apr; 27(2):188-92. PubMed ID: 17414244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depression in methadone maintenance treatment patients: rate and risk factors.
    Peles E; Schreiber S; Naumovsky Y; Adelson M
    J Affect Disord; 2007 Apr; 99(1-3):213-20. PubMed ID: 17055063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical use of methadone.
    Layson-Wolf C; Goode JV; Small RE
    J Pain Palliat Care Pharmacother; 2002; 16(1):29-59. PubMed ID: 14650449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid addicts at admission vs. slow-release oral morphine, methadone, and sublingual buprenorphine maintenance treatment participants.
    Giacomuzzi S; Kemmler G; Ertl M; Riemer Y
    Subst Use Misuse; 2006; 41(2):223-44. PubMed ID: 16393744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Slow-release oral morphine for maintenance treatment of opioid addicts intolerant to methadone or with inadequate withdrawal suppression.
    Kastelic A; Dubajic G; Strbad E
    Addiction; 2008 Nov; 103(11):1837-46. PubMed ID: 19032534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Slow tapering from methadone maintenance in a program encouraging indefinite maintenance.
    Calsyn DA; Malcy JA; Saxon AJ
    J Subst Abuse Treat; 2006 Mar; 30(2):159-63. PubMed ID: 16490679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid plasma concentrations in methadone-and buprenorphine-maintained patients.
    Jagsch R; Gombas W; Schindler SD; Eder H; Moody DE; Fischer G
    Addict Biol; 2005 Dec; 10(4):365-71. PubMed ID: 16318959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone.
    McCambridge J; Gossop M; Beswick T; Best D; Bearn J; Rees S; Strang J
    Drug Alcohol Depend; 2007 Apr; 88(1):91-5. PubMed ID: 17064857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Buprenorphine or methadone for detoxification of young opioid addicts?].
    Ebner R; Schreiber W; Zierer C
    Psychiatr Prax; 2004 Nov; 31 Suppl 1():S108-10. PubMed ID: 15570521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychosis in the opioid addicted patient: assessment and treatment.
    Uhde TW; Redmond DE; Kleber HD
    J Clin Psychiatry; 1982 Jun; 43(6):240-7. PubMed ID: 7085579
    [No Abstract]   [Full Text] [Related]  

  • 20. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone.
    Seifert J; Metzner C; Paetzold W; Borsutzky M; Passie T; Rollnik J; Wiese B; Emrich HM; Schneider U
    Pharmacopsychiatry; 2002 Sep; 35(5):159-64. PubMed ID: 12237786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.